How Analysts Feel About Opko Health Inc. (OPK) After Achieving Yearly Low?

Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $23,047,822.01. (NASDAQ:OPK) by 0.5% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

On Monday, May 22nd, Phillip Md Et Al Frost acquired 120,000 shares of Opko Health stock. The insider shares were bought at average $6.4 of a share, and $270,959 United States dollars , making this deal a considerable one. The stock was bought at an average cost of $6.93 per share, for a total transaction of $138,600.00. The shares were bought at an average price of $6.54 per share, with a total value of $463,032.00. 112,975 shares were sold by Logal Adam, worth $911,674.

The share price of the company (NASDAQ:OPK) was down -1.36%, with a high of 6.59 during the day and the volume of Opko Health Inc shares traded was 4235969. Floating stock is calculated by subtracting closely-held shares and restricted stock from a firm's total outstanding shares. State Street Corp now owns 7,787,875 shares of the biotechnology company's stock valued at $72,427,000 after buying an additional 226,132 shares during the last quarter. Highlander Mngmt Lc stated it has 0.13% of its portfolio in Opko Health Inc. (NASDAQ:OPK) have received an average recommendation of "Hold" from the ten research firms that are now covering the company. The company's market capitalization is $3.70 billion. The Return on Equity ratio of Opko Health, Inc. The stock has a 50-day moving average of $7.42 and a 200 day moving average of $8.85.

The company is scheduled to announce its next quarterly financial results on 14/08/2017 after the market close. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by $0.02. Last session Opko Health, Inc.

The company's expected revenue in the current quarter to be 322.64 Million, seeing a projected current quarter growth of -350%, and per annum growth estimates over the next 5 year period of around 12%.

Shares of the company have shown an EPS growth of -7.60% in the last 5 years. While in the same Quarter Previous year, the Actual EPS was $0.02.

Incyte Corporation has a higher fundamental rating than Opko Health Inc which has an impact on the head-to-head comparison. Vanguard Group Inc. raised its stake in Opko Health by 4.4% in the first quarter. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US & worldwide trademark and copyright legislation. If you are accessing this news story on another website, it was stolen and reposted in violation of USA & worldwide trademark and copyright legislation.

Zacks Investment Research cut shares of Opko Health Inc. Formidable Asset Management LLC increased its position in shares of Opko Health by 10.4% in the fourth quarter. World Asset Management Inc now owns 15,176 shares of the biotechnology company's stock worth $121,000 after buying an additional 2,900 shares in the last quarter. Russell Investments Group Ltd. bought a new position in shares of Opko Health during the fourth quarter valued at approximately $648,000. Russell Investments Group Ltd. purchased a new stake in shares of Opko Health during the fourth quarter worth about $648,000. The company presently has a consensus rating of "Hold" and an average price target of $15.64.

A stock rating usually tells investors how well a stock's market value relates to what analysts think is a fair value for the stock, based on an independent evaluation of the company.

Several analysts have commented on the stock. Guggenheim started coverage on Opko Health in a research report on Tuesday, March 14th. They set a "buy" rating and a $25.00 target price for the company. Standpoint Research reissued a "buy" rating and issued a $14.00 target price on shares of Opko Health in a research report on Sunday, March 5th.

Opko Health Inc (OPK) now has P/E (Price to Earnings) ratio of 0 while the company's industry has 14.32 P/E and the sector P/E is 17.37. Cambridge Research Advsrs holds 0.09% of its portfolio in Opko Health Inc. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company's stock. The company has a consensus rating of "Hold" and a consensus target price of $15.64.

  • Zachary Reyes